<unk>  is a drug candidate molecule under investigation to treat Alzheimer's disease. It targets the enzyme O-GlcNAcase. Its result is to reduce formation of tau protein tangles. A molecule containing radioactive fluorine was used with a PET scan to show that<unk>  binds in the human brain. Eli Lilly and Company is recruiting subjects for a clinical trial. Some hospitals in Australia: St Vincent's Hospital, Sydney Hornsby Ku-Ring-Gai Hospital, The Prince Charles Hospital, The Queen Elizabeth Hospital, Adelaide, Box Hill Hospital, and Delmont Private Hospital are involved. Results of the trial are expected by June 2024.
LY3372689
DCW234
ABC 
MIS416
ACDC 
McN5652
P14arf
PC3